Results 21 to 30 of about 82,478 (265)

Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer

Endocrine Connections, 2019
To date, no research evaluating the predictive capabilities of soluble programmed cell death-ligand 1 (sPD-L1) in thyroid cancer patients has been performed.
Marra Jai Aghajani, Tara Laurine Roberts, Tao Yang, Charles Eugenio McCafferty, Nicole J Caixeiro, Paul DeSouza, Navin Niles   +6 more
doaj   +2 more sources

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance

OncoImmunology, 2020
ADAM10 and ADAM17 expression and soluble PD-L1 (sPD-L1) predict poor prognosis in many malignancies, including in patients treated with PD-(L)1 inhibitors. The mechanism of soluble PD-L1 production and its effects are unknown.
Jacob J. Orme, Khalid A. Jazieh, Tiancheng Xie, Susan Harrington, Xin Liu, Matthew Ball, Benjamin Madden, M. Cristine Charlesworth, Tariq U. Azam, Fabrice Lucien, Bharath Wootla, Yanli Li, Jose Caetano Villasboas, Aaron S. Mansfield, Roxana S. Dronca, Haidong Dong   +15 more
doaj   +2 more sources

Study of the clinicopathological features of soluble PD-L1 in lung cancer patients

Journal of Rural Medicine, 2023
Objective: In recent years, an association between serum soluble immune checkpoint molecules (sICMs) and malignant tumors has been reported, which may become important biomarkers in the future. Although several reports have suggested a correlation between sICMs and prognosis, their origin is unclear.
Sasaki, Takanobu, Nonomura, Ryo, Tabata, Toshiharu, Yoshimura, Naruo, Hata, Shuko, Shimada, Hiroki, Nakamura, Yasuhiro   +6 more
openaire   +3 more sources

Novel ultrasensitive automated kinetic exclusion assay for measurement of plasma levels of soluble PD-L1, the predictive and prognostic biomarker in cancer patients treated with immune checkpoint inhibitors

Heliyon
Recently, the blood plasma or serum levels of soluble programmed death protein 1 (PD-L1), but not tissue PD-L1 expression level, have been proposed as an effective predictive and prognostic biomarker in patients treated with immune checkpoint inhibitors ...
Ibrahim A. Darwish, Waleed Alahmad, Rajendran Vinoth   +2 more
doaj   +2 more sources

Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism [PDF]

Frontiers in Immunology, 2018
Viruses often subvert antiviral immune responses by taking advantage of inhibitory immune signaling. We investigated if hantaviruses use this strategy.
Martin J. Raftery, Mohammed O. Abdelaziz, Jörg Hofmann, Günther Schönrich   +3 more
doaj   +2 more sources

Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy

Cancer Management and Research, 2021
Rong Fu,1 Chuan-Qing Jing,1 Xiu-Rong Li,2 Zhao-Feng Tan,2 Hui-Jie Li2 1Clinical Department of Integrated Traditional Chinese and Western Medicine, The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, People ...
Fu R, Jing CQ, Li XR, Tan ZF, Li HJ
doaj   +1 more source

Soluble Expression of Small Antibody Fragments against PD-L1 Using Escherichia coli with High Yield and Purity

Applied Sciences, 2021
Programmed death-ligand 1 (PD-L1) is a surface protein overexpressed in tumor cells. Recently, targeted therapy using PD-L1 antibodies to reconstitute the antitumor activity of T cells has received considerable attention as a cancer treatment.
Sun-Hee Kim, Hee-Jin Jeong
doaj   +2 more sources

Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study [PDF]

Critical Care, 2018
Background Sepsis remains a major cause of mortality in critical care, for which specific treatments are lacking. The dysregulated response to infection seen in sepsis includes features of lymphocyte dysfunction and exhaustion, suggesting that immune ...
Julie K. Wilson, Yuan Zhao, Mervyn Singer, Jo Spencer, Manu Shankar-Hari   +4 more
doaj   +2 more sources

Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade [PDF]

The Journal of Clinical Investigation
BACKGROUND Precise stratification of patients with non–small cell lung cancer (NSCLC) is needed for appropriate application of PD-1/PD-L1 blockade therapy.METHODS We measured soluble forms of the immune-checkpoint molecules PD-L1, PD-1, and CTLA-4 in ...
Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, Takashi Kurosaki, Yosuke Togashi, Kazuya Fukuoka, Megumi Goto, Yasutaka Chiba, Shuta Tomida, Takayo Ota, Koji Haratani, Takayuki Takahama, Junko Tanizaki, Takeshi Yoshida, Tsutomu Iwasa, Kaoru Tanaka, Masayuki Takeda, Tomoko Hirano, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Kazuko Sakai, Keiko Higuchi, Hitoshi Uga, Chihiro Suminaka, Toyohiro Hirai, Kazuto Nishio, Kazuhiko Nakagawa, Tasuku Honjo   +28 more
doaj   +2 more sources

ASSOCIATION BETWEEN LONGITUDINAL CHANGES IN SERUM SOLUBLE PD-L1 LEVELS AND NEUTROPHIL PD-L1 MRNA EXPRESSION WITH OUTCOME IN A HETEROGENEOUS GENERAL ICU POPULATION

Shock
ABSTRACT Introduction: Immunosuppression is a common phenomenon in critically ill patients, regardless of sepsis presence. The interaction between programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) is believed to play a significant role in immunosuppression.
Stelios Kokkoris, Chrysi Keskinidou, Edison Jahaj, Nikolaos Lotsios, Charikleia S. Vrettou, Georgios Ferentinos, Vassiliki Giannopoulou, Aikaterini Koutsi, Anastasia Kotanidou, Ioanna Dimopoulou, Alice G. Vassiliou   +10 more
openaire   +4 more sources